Fax: (801) 585-0159
Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain†
A long-term, open-label safety study
Version of Record online: 16 APR 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 11, pages 2571–2579, 1 June 2009
How to Cite
Weinstein, S. M., Messina, J. and Xie, F. (2009), Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain. Cancer, 115: 2571–2579. doi: 10.1002/cncr.24279
The authors thank the investigators: Jacob Abraham, MD; Andrea Baxter, MD; Patrick Beatty, MD; Ali Ben-Jacob, MD; Donald Berdeaux, MD; Debra Brandt, MD; Donald Brooks, MD; Daniel Buffington, MD; Jennifer Caskey, MD; Veena Charu, MD; Michael Drass, MD; David Ellison, MD; Orlando Florete, MD; Nashat Gabrail, MD; Gregory Guzley, MD; Martin E. Hale, MD; Youssef Hanna, MD; Mohamed Haq, MD; Jeffrey Hines, MD; Timothy Houden, MD; Haresh Jhangiani, MD; Edward Kaplan, MD; Ronald Kawauchi, MD; Christine Laramee, MD; Gary Lee, MD; Luis A. Meza, MD; Johnny Nacilla, MD; Srinivas Nalamachu, MD; Ravi Patel, MD; John Peppin, DO; Dat Pham, MD; J. Talisman Pomeroy, MD; Russell Portenoy, MD; Richard Rauck, MD; Prabhakara Reddy, MD; Evangeline Reyes, MD; John Roberts, MD; Marc Saltzman, MD; Thalia Segal, MD; Neal Slatkin, MD; Scott Sonnier, MD; Raymond Sorensen, MD; Forrest Swan, MD; Donald Taylor, MD; Howard Terebelo, MD; Rajbala Thakur, MD; John Thropay, MD; James Weick, MD; and Michael Wertheim, MD.
- Issue online: 20 MAY 2009
- Version of Record online: 16 APR 2009
- Manuscript Accepted: 17 NOV 2008
- Manuscript Revised: 14 NOV 2008
- Manuscript Received: 21 AUG 2008
Vol. 115, Issue 14, 3372, Version of Record online: 26 MAY 2009
- breakthrough pain;
- cancer pain;
- fentanyl buccal tablet;
- long-term therapy;
This study assessed the long-term safety and tolerability of fentanyl buccal tablet (FBT) in opioid-tolerant patients with cancer and breakthrough pain (BTP) who were either naive to FBT or had completed 1 of 2 previous double-blind, placebo-controlled FBT studies (rollover patients).
Patients who were FBT-naive underwent titration to find a successful FBT dose. Rollover patients used a previously identified successful dose of FBT. Patients who achieved a successful dose were eligible to enter a maintenance phase (≥12 months). Safety assessments included adverse events (AEs), physical and neurologic examinations, and clinical laboratory tests.
Two hundred thirty-two patients were enrolled. A total of 112 entered titration; 79 identified a successful FBT dose, and 77 of these patients entered the maintenance phase along with 120 rollover patients (n = 197). AEs resulted in discontinuation of therapy for 33% of patients. The most common AEs were generally typical of opioids administered to cancer patients. All serious AEs were considered to be related to the patients' underlying conditions, except for 1 incident of FBT-related drug withdrawal syndrome. Sixty patients died after enrollment because of disease progression. Fifteen (6%) patients experienced ≥1 application-site AE, all of which were considered by investigators to be related to FBT.
FBT was generally well tolerated and had a favorable safety profile in the long-term (≥12 months) management of patients with persistent cancer pain and BTP. No unexpected AEs occurred. Safety and tolerability was similar to that observed in short-term studies. Cancer 2009. © 2009 American Cancer Society.